cervical intraepithelial neoplasia


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

neoplasia

 [ne″o-pla´zhah]
the formation of a neoplasm.
cervical intraepithelial neoplasia (CIN) dysplasia of the cervical epithelium, often premalignant, characterized by various degrees of hyperplasia, abnormal keratinization, and the presence of condylomata.
multiple endocrine neoplasia (MEN) a group of rare hereditary disorders of autonomous hyperfunction of more than one endocrine gland. In Type I (MEN I), called also Wermer's syndrome, there are tumors of the pituitary, parathyroid gland, and pancreatic islet cells in association with a high incidence of peptic ulcer. Type II (MEN II), called also Sipple's syndrome, is characterized by medullary carcinoma of the thyroid, pheochromocytoma, often bilateral and multiple, and parathyroid hyperplasia. Type III (MEN III), called also mucosal neuroma syndrome, resembles Type II except that parathyroid hyperplasia is rare, the mean survival time is shorter, and there may be neuromas and neurofibromas. All forms are transmitted as autosomal dominant traits.

cer·vi·cal in·tra·ep·i·the·li·al ne·o·pla·si·a (CIN),

dysplastic changes beginning at the squamocolumnar junction in the uterine cervix that may be precursors of squamous cell carcinoma: grade 1, mild dysplasia involving the lower one third or less of the epithelial thickness; grade 2, moderate dysplasia with one third to two thirds involvement; grade 3, severe dysplasia or carcinoma in situ, with two thirds to full-thickness involvement.

cervical intraepithelial neoplasia (CIN)

[in′trə·ep′ithē′lē·əl]
abnormal changes in the basal layers of the squamous epithelial tissues of the uterus. The disorder is graded according to its pathological progress, from CIN1 to CIN3; CIN3 represents carcinoma of the cervix. The disorder is associated with human papillomaviruses.

cervical intraepithelial neoplasia

Cervical dysplasia, CIN Gynecology Precancerous change of uterine cervical epithelium Screening Pap smears, colposcopy and pelvic exam Peak age 25 to 35 Risk factors Multiple sexual partners, early onset of sexual activity–< age 18, early childbearing–< age 16, Hx of STDs–eg, genital warts, genital herpes, HIV; CIN represents a continuum of histologic changes ranging from CIN 1–formerly, mild dysplasia, to severe dysplasia/carcinoma in situ, CIN 3; the lesion arises at the squamocolumnar cell junction at the transformation zone of the endocervical canal, with a variable tendency to develop invasive SCC, a tendency that is enhanced by concomitant HPV infection, of which HPV 6 and 11 are associated with the 'garden variety', ie benign condylomas; HPV types 16, 18 occur in CIN 3; types 31, 33, 35, 52, 56 also occur in CIN; 78% of ♀ who are positive for HPV, especially HPV 16 and 18, eventually develop CIN 2-3 Treatment Cone biopsy, laser vaporization or excision, loop electrosurgical excision, cryotherapy. See Carcinoma-in-situ, Cervical cancer, Intraepithelial neoplasia, Dysplasia, Low-grade intraepithelial neoplasia, High-grade intraepithelial neoplasia.
Progression of Cervical Intraepithelial Neoplasia
CIN 1 CIN 2 CIN 3
Regression 60%/50% 40%/43% 33%/–
Persistence 30%/41% 40%/48% 55%/–
Progression to CIN 3 10%/9% 20%/9% NA
Progression to SCC ± 1% 5% ≥ 12%
From Int J Gynecol Pathol 1993; 12:186/Modern Pathol 1990; 3:679.

cer·vi·cal in·tra·ep·i·the·li·al ne·o·pla·si·a

(CIN) (sĕr'vi-kăl in'tră-ep-i-thē'lē-ăl nē-ō-plā'zē-ă)
Dysplastic changes beginning at the squamocolumnar junction in the uterine cervix that may be precursors of squamous cell carcinoma: Grade 1, mild dysplasia involving the lower one third or less of the epithelial thickness; Grade 2, moderate dysplasia with one third to two thirds involvement; and Grade 3, severe dysplasia or carcinoma in situ, with two thirds to full-thickness involvement.

cervical intraepithelial neoplasia (CIN)

A cancer of the cervix that is still confined to the outer layer, the epithelium, and is readily curable. CIN is graded I to III depending on the degree of severity. The principal cause of CIN is the human papillomavirus type 16, and promiscuous sexual intercourse with men is an important risk factor for cervical cancer. But about 1 woman in 5 who have never had heterosexual intercourse carries the papillomavirus.

Cervical intraepithelial neoplasia (CIN)

A term used to categorize degrees of dysplasia arising in the epithelium, or outer layer, of the cervix.
Mentioned in: Cervical Cancer, Pap Test
References in periodicals archive ?
Kovanda A, Juvan U, Sterbenc A, et at, Pre-vaccination distribution at human papillomavirus (HPV) genotypes in women with cervical intraepithelial neoplasia grade 3 (CIN 3) lesions in Slovenia.
The relationship of community-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses.
The analysis showed an adjusted excess hazard for developing cervical intraepithelial neoplasia (CIN) I of 53%, compared with the general population, and an excess 39% rate of CIN II or III, both statistically significant differences, Dr.
The trial which is being conducted at three leading gynecological oncology centers in the United States is designed to evaluate the safety, feasibility and immunological responses of the novel Versamune(TM)-based PDS0101 cancer immunotherapy in patients with cervical intraepithelial neoplasia.
The ASCCP has determined guidelines for conventional management of cervical intraepithelial neoplasia or adenocarcinoma in situ.
Cervical screening and management of cervical intraepithelial neoplasia in HIV-positive women.
Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia.
Of the 2,188 who underwent colposcopy at BSMMU, 157 were diagnosed with cervical intraepithelial neoplasia (CIN) 2-3 and 123 with invasive cancer.
from cervicitis through cervical intraepithelial neoplasia (CIN) I, II, and III to squamous cell carcinoma (SCC) of the cervix.
Women who have had a total hysterectomy and no history of high-grade cervical intraepithelial neoplasia should discontinue cervical cancer screening altogether.
The FDA's Vaccines and Related Biological Products Advisory Committee, voted 12-1 that data on the Glaxo-SmithKline Biolog-icals HPV bivalent (types 16 and 18) vaccine, recombinant, supported the efficacy of the vaccine for preventing HPV 16/ 18-re-lated cervical cancer, cervical intraepithelial neoplasia (CIN) 2+, adenocarcinoma in situ (AIS), and CIN1+ in girls and women aged 15-25 years.

Full browser ?